Title:Trabectedin in Cancers: Mechanisms and Clinical Applications
Volume: 28
Issue: 24
Author(s): Jiali Wang, Pengfei Wang, Zheng Zeng, Caiji Lin, Yiru Lin, Danli Cao, Wenqing Ma, Wenwen Xu, Qian Xiang, Lingjie Luo, Wenxue Wang, Yongwei Shi, Zixiang Gao, Yufan Zhao, Huidi Liu*Shu-Lin Liu*
Affiliation:
- College of Pharmacy, Genomics Research Center (State-Province Key Laboratories of Biomedicine Pharmaceutics of China),
Harbin Medical University, Harbin, China
- HMU-UCCSM Centre for Infection and Genomics, Harbin, 150081, China
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences,
Heilongjiang, China
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4N1, Canada
- College of Pharmacy, Genomics Research Center (State-Province Key Laboratories of Biomedicine Pharmaceutics of China),
Harbin Medical University, Harbin, China
- HMU-UCCSM Centre for Infection and Genomics, Harbin, 150081, China
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences,
Heilongjiang, China
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4N1, Canada
- Department of
Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, T2N 4N1, Canada
Keywords:
Trabectedin, anticancer, tissue sarcomas, combined drug use, malignancies, antineoplastic agent, tumor microenvironment.
Abstract: Trabectedin, a tetrahydroisoquinoline alkaloid, is the first marine antineoplastic agent approved with
special anticancer mechanisms involving DNA binding, DNA repair pathways, transcription regulation and
regulation of the tumor microenvironment. It has favorable clinical applications, especially for the treatment of
patients with advanced soft tissue sarcoma, who failed in anthracyclines and ifosfamide therapy or could not
receive these agents. Currently, trabectedin monotherapy regimen and regimens of combined therapy with other
agents are both widely used for the treatment of malignancies, including soft tissue sarcomas, ovarian cancer,
breast cancer, and non-small-cell lung cancer. In this review, we have summarized the basic information and
some updated knowledge on trabectedin, including its molecular structure, metabolism in various cancers,
pharmaceutical mechanisms, clinical applications, drug combination, and adverse reactions, along with prospects
of its possibly more optimal use in cancer treatment.